The Arcalyst (rilonacept) Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of Arcalyst (rilonacept) has experienced substantial growth in recent years. This market was valued at $221.19 million in 2024 and is projected to reach $239.88 million in 2025. The compound annual growth rate (CAGR) for this time period is estimated to be 8.5%.
The Arcalyst (rilonacept) global market is forecasted to grow to a size of $311.73 million in 2029, with a compound annual growth rate (CAGR) of 6.8%.
Download Your Free Sample of the 2025 Arcalyst (rilonacept) Market Report and Uncover Key Trends Now!The key drivers in the arcalyst rilonacept market are:
• Rising demand for personalized medicines tailored to individual patient characteristics
• Increased recognition and diagnostic tools identifying genetically driven conditions treatable with Arcalyst
• Growing number of people diagnosed with conditions that Arcalyst can treat
• Significant advancements in new drug approvals, particularly for personalized medicines
The arcalyst (rilonacept) market covered in this report is segmented –
1) By Type: Lyophilized, Liquid
2) By Indication: Cryopyrin-Associated Periodic Syndromes (CAPS), Deficiency Of Interleukin-1 Receptor Antagonist (DIRA), Other Indications
3) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Adult Patients, Pediatric Patients
The key trends in the arcalyst rilonacept market are:
• Advancements in biologic therapies for autoimmune conditions are a key trend.
• Collaborations between pharmaceutical companies are increasingly shaping the market.
• Precision medicine and targeted therapies are advancing rapidly.
• Technological advancements and innovations in drug delivery systems are transforming the industry.
Major players in the arcalyst rilonacept market are:
• Regeneron Pharmaceuticals Inc.
• Kiniksa Pharmaceuticals Ltd.
North America had the largest share in the Arcalyst (rilonacept) market in 2024.